PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Lung Cancer10.1016/s0169-5002(20)30143-42020139S51Real-world data of using durvalumab in stage III non-small cell lung cancer (NSCLC): West Midlands experienceA. Jegannathenhttps://api.elsevier.com/content/article/PII:S0169500220301434?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500220301434?httpAccept=text/plain
Lung Cancer10.1016/j.lungcan.2017.11.0122018126210-216Real life experience with nivolumab for the treatment of non-small cell lung carcinomaRobert D. Schouten, Mirte Muller, Cornedine J. de Gooijer, Paul Baas, Michel van den Heuvelhttps://api.elsevier.com/content/article/PII:S016950021730569X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S016950021730569X?httpAccept=text/plain
Lung Cancer10.1016/s0169-5002(18)30112-02018115S35-S36Real world efficacy of nivolumab for non-small cell lung cancer (NSCLC) in the West of Scotland (WoS)S. Ansel, R. Rulach, B. Clark, N. Steele, V. Maclarenhttps://api.elsevier.com/content/article/PII:S0169500218301120?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500218301120?httpAccept=text/plain
Cancer Reports10.1002/cnr2.14872021Real‐world experience of nivolumab in the treatment of poor performance status patients with advanced non‐small cell lung cancerM. Nazim Abbas, Myron Klevansky, Bogda Koczwara, Amitesh Chandra Roy, Shawgi Sukumaran, Sina Vatandoust, Christos Stelios Karapetishttps://onlinelibrary.wiley.com/doi/pdf/10.1002/cnr2.1487, https://onlinelibrary.wiley.com/doi/full-xml/10.1002/cnr2.1487, https://onlinelibrary.wiley.com/doi/pdf/10.1002/cnr2.1487
Lung Cancer10.1016/s0169-5002(20)30151-32020139S54Real world experience of immunotherapy in elderly patients with advanced non-small cell lung carcinoma: a retrospective studyM. Tilby, H.C. Ghanta, A. Jainhttps://api.elsevier.com/content/article/PII:S0169500220301513?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500220301513?httpAccept=text/plain
Lung Cancer10.1016/s0169-5002(18)30101-62018115S31The use of second or third line nivolumab in advanced non-small cell lung cancer: a west of Scotland experienceC. Ali, K. Yahyahttps://api.elsevier.com/content/article/PII:S0169500218301016?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500218301016?httpAccept=text/plain
Lung Cancer10.1016/s0169-5002(19)30134-52019127S39Real world treatment and outcomes in patients with EGFR mutation positive advanced non-small cell lung cancer: the Kent Cancer Network experienceV. Angelis, M. Fenton, S. Hunter, R. Shahhttps://api.elsevier.com/content/article/PII:S0169500219301345?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500219301345?httpAccept=text/plain
South Asian Journal of Cancer10.4103/sajc.sajc_111_192020090150-52The real-world experience with nivolumab in previously treated patients with advanced non-small cell lung cancer from a cancer center in IndiaWaseem Abbas, Rudra Prasad Acharya, Archit Pandit, Saurabh Gupta, Ranga Raju Raohttp://www.thieme-connect.de/products/ejournals/pdf/10.4103/sajc.sajc_111_19.pdf
Lung Cancer10.1016/s0169-5002(20)30140-92020139S49A real-world experience of immune checkpoint inhibitors: immunotherapy related adverse events for locally advanced and metastatic non-small cell lung cancerL. Sidon, M. Dillon, D. Power, S. Dubashhttps://api.elsevier.com/content/article/PII:S0169500220301409?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500220301409?httpAccept=text/plain
Cancer Science10.1111/cas.151172021Real‐world safety of nivolumab in patients with non‐small‐cell lung cancer in Japan: Postmarketing surveillanceNobuyuki Yamamoto, Yoichi Nakanishi, Akihiko Gemma, Kazuhiko Nakagawa, Takahiko Sakamoto, Ayumi Akamatsu, Yuichiro Ohehttps://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.15117, https://onlinelibrary.wiley.com/doi/full-xml/10.1111/cas.15117, https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.15117